Key result
Percutaneous left atrial appendage exclusion devices offer a safe and feasible alternative for stroke prevention in patients with atrial fibrillation who are ineligible for oral anticoagulation.
Why the study?
Does percutaneous left atrial appendage exclusion therapy prevent ischemic strokes compared to oral anticoagulation?
Does percutaneous left atrial appendage exclusion therapy prevent ischemic strokes compared to oral anticoagulation?
Percutaneous left atrial appendage exclusion therapy is a safe and feasible alternative to oral anticoagulation for stroke prevention.
Answers are grounded in this paper and cite their sources.
Supports LAA exclusion in OAC-ineligible AF; leaves open randomized comparisons to anticoagulation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Möbius‐Winkler et al. (2009) conducted a review in Atrial fibrillation. Percutaneous Left Atrial Appendage Exclusion (WATCHMAN, PLAATO, Amplatzer) vs. Oral anticoagulation (warfarin) was evaluated. Percutaneous left atrial appendage exclusion devices offer a safe and feasible alternative for stroke prevention in patients with atrial fibrillation who are ineligible for oral anticoagulation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: